Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Basic): 2010-2024

Historic EPS (Basic) for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$0.27.

  • China Pharma Holdings' EPS (Basic) rose 73.85% to -$0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.41, marking a year-over-year increase of 161.84%. This contributed to the annual value of -$0.27 for FY2024, which is 70.33% up from last year.
  • As of FY2024, China Pharma Holdings' EPS (Basic) stood at -$0.27, which was up 70.33% from -$0.91 recorded in FY2023.
  • China Pharma Holdings' 5-year EPS (Basic) high stood at -$0.07 for FY2020, and its period low was -$3.78 during FY2022.
  • For the 3-year period, China Pharma Holdings' EPS (Basic) averaged around -$1.65, with its median value being -$0.91 (2023).
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 85.42% in 2020, then plummeted by 957.14% in 2021.
  • Yearly analysis of 5 years shows China Pharma Holdings' EPS (Basic) stood at -$0.07 in 2020, then slumped by 957.14% to -$0.74 in 2021, then slumped by 410.81% to -$3.78 in 2022, then soared by 75.93% to -$0.91 in 2023, then surged by 70.33% to -$0.27 in 2024.